Last reviewed · How we verify
Placebo lead in
Placebo lead in is a Small molecule drug developed by Technische Universität Dresden. It is currently in Phase 3 development.
Placebo lead-in is a study design phase where patients receive placebo before randomization to active treatment, used to establish baseline disease progression and identify placebo responders.
At a glance
| Generic name | Placebo lead in |
|---|---|
| Sponsor | Technische Universität Dresden |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo lead-in period is a methodological approach in clinical trials where all enrolled patients initially receive placebo for a defined duration. This allows researchers to measure natural disease progression, establish stable baseline measurements, and identify patients with high placebo response rates who may be excluded from the main randomized phase. This design strengthens the ability to detect true drug effects by reducing noise from placebo responders.
Approved indications
Common side effects
Key clinical trials
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (PHASE3)
- Biomarker-based Trial of NPC-1 for Alzheimer's Pathology (PHASE1, PHASE2)
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (PHASE2, PHASE3)
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract (PHASE3)
- Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma (PHASE2)
- A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity (PHASE1)
- Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (PHASE2, PHASE3)
- Avatrombopag vs. Placebo for CIT in GI Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo lead in CI brief — competitive landscape report
- Placebo lead in updates RSS · CI watch RSS
- Technische Universität Dresden portfolio CI
Frequently asked questions about Placebo lead in
What is Placebo lead in?
How does Placebo lead in work?
Who makes Placebo lead in?
What development phase is Placebo lead in in?
Related
- Manufacturer: Technische Universität Dresden — full pipeline
- Compare: Placebo lead in vs similar drugs
- Pricing: Placebo lead in cost, discount & access